At what enterprise value was OBAGI MEDICAL acquired in 2026?

During the acquisition of OBAGI MEDICAL by BRIDGEPOINT in 2026, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of OBAGI MEDICAL when it was acquired by BRIDGEPOINT?

The estimated EV/EBITDA multiple for OBAGI MEDICAL is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was OBAGI MEDICAL acquired by BRIDGEPOINT?

OBAGI MEDICAL was acquired by BRIDGEPOINT in 2026.

What was the revenue of OBAGI MEDICAL at the time of the deal?

The revenue of OBAGI MEDICAL at the time of the deal is estimated to be in the range of 100M - 200M USD. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of OBAGI MEDICAL during the acquisition?

OBAGI MEDICAL's EBITDA is estimated to be in the range of 5M - 25M USD. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the OBAGI MEDICAL acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the OBAGI MEDICAL deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.bridgepointgroup.com/about-us/news-and-insights/press-releases/2026/bridgepoint-agrees-to-acquire-obagi-medical

← DATABASE

Home Database Healthcare & PharmaOBAGI MEDICAL

06/2026

OBAGI MEDICAL acquired by BRIDGEPOINT

UNITED STATES Life Sciences / Pharma & Biotech / Generics / Labs EV 300M - 700M USD

Context

Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets. The transaction reflects a strategy focused on building specialised platforms within dermatology and aesthetics, supported by structural growth driven by the medicalisation of skincare routines and the convergence of beauty and healthcare. Bridgepoint aims to build an integrated platform of clinical skincare and aesthetics brands covering a broader spectrum of solutions, from dermatological treatments to injectable aesthetic products. The acquisition of Obagi provides exposure to a leading physician-dispensed brand with a recurring professional customer base and strong alignment with global trends in medicalised skincare. The industrial rationale is based on convergence between medical skincare and injectable aesthetics, with potential synergies in professional distribution, product development and geographic expansion.

OBAGI MEDICAL, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , a level than the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Obagi Medical is a medical-grade skincare company operating at the intersection of dermatology, aesthetics and professionally guided consumer skincare. The company develops and markets clinically formulated products based on skin biology research, addressing key concerns such as premature ageing, hyperpigmentation, acne, sun damage and photodamage. Its business model is primarily centred on the professional and physician-dispensed channel, including dermatologists, aesthetic practitioners and healthcare professionals. A significant share of its portfolio is prescribed or recommended within clinical settings, while additional products are available through in-office retail and digital channels. Obagi has progressively expanded its international footprint across North America, Europe, Asia and the Middle East, leveraging its professional distribution network and digital growth strategy.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2026	YOTTA CAPITAL / OUEST CROISSANCE	Les Laboratoires Herbolistique	FRANCE	Nutrition & Dietary Supplements
07/2026	BAIN CAPITAL	Vitabiotics	UNITED KINGDOM	Nutrition & Dietary Supplements
06/2026	3I	LABORATOIRE NUTERGIA	FRANCE	Nutrition & Dietary Supplements
06/2026	CORDENPHARMA	AMBIOPHARM	UNITED STATES	CDMO
06/2026	MOTION EQUITY PARTNERS	POLARIS	FRANCE	Nutrition & Dietary Supplements
06/2026	COLUMBUS VENTURE PARTNERS / MERIEUX EQUITY PARTNERS	ONA THERAPEUTICS	SPAIN	R&D Biotech
06/2026	DHCARE	OTTOBOCK HUMAN MOBILITY	GERMANY	Medical Devices
06/2026	ABBVIE	APOGEE THERAPEUTICS	UNITED STATES	R&D Biotech
05/2026	STRYKER	AMPLITUDE VASCULAR SYSTEMS	UNITED STATES	Medical Devices
04/2026	RANTUM CAPITAL	TONTARRA MEDIZINTECHNIK	GERMANY	Medical Devices

REFERENCES

Valuation range: EV 300M - 700M USD

Revenue range: 100M - 200M USD

EBITDA range: 5M - 25M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OBAGI MEDICAL by BRIDGEPOINT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: obagi medical

Acquirer: bridgepoint